Invention Grant
- Patent Title: Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
-
Application No.: US16805196Application Date: 2020-02-28
-
Publication No.: US11040024B2Publication Date: 2021-06-22
- Inventor: George W. Muller , Peter H. Schafer , Hon-Wah Man , Chuansheng Ge
- Applicant: AMGEN INC.
- Applicant Address: US CA Thousand Oaks
- Assignee: AMGEN INC.
- Current Assignee: AMGEN INC.
- Current Assignee Address: US CA Thousand Oaks
- Agency: Marshall, Gerstein & Borun LLP
- Main IPC: A61K31/4035
- IPC: A61K31/4035 ; C07C317/28 ; A61K45/06 ; C07D209/48
![Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione](/abs-image/US/2021/06/22/US11040024B2/abs.jpg.150x150.jpg)
Abstract:
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.
Public/Granted literature
Information query
IPC分类: